Search company, investor...

Human Genome Sciences

hgsi.com

Founded Year

1992

Stage

Acq - P2P | Acquired

Valuation

$0000 

Revenue

$0000 

About Human Genome Sciences

Human Genome Sciences is a development stage company that was formed to develop and commercialize therapeutically enhanced proprietary biopharmaceuticals with the aim of offering significant reductions in dosage, injection frequency, side effects, and overall cost of treatment. In July 2012, Human Genome Sciences was acquired by GlaxoSmithKline. The valuation of Human Genome Sciences was $3.6 billion.

Headquarters Location

14200 Shady Grove Road

Rockville, Maryland, 20850,

United States

Missing: Human Genome Sciences's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Human Genome Sciences's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Human Genome Sciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Human Genome Sciences is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Human Genome Sciences Patents

Human Genome Sciences has filed 137 patents.

The 3 most popular patent topics include:

  • Audio equipment manufacturers
  • Audio engineering
  • Headphones manufacturers
patents chart

Application Date

Grant Date

Title

Related Topics

Status

5/3/2019

3/9/2021

Headphones manufacturers, Audio equipment manufacturers, Hearing, DOS games, Radio electronics

Grant

Application Date

5/3/2019

Grant Date

3/9/2021

Title

Related Topics

Headphones manufacturers, Audio equipment manufacturers, Hearing, DOS games, Radio electronics

Status

Grant

Latest Human Genome Sciences News

Human Genome Sciences Alumni: Where Are They Now?

Oct 18, 2022

HGS alumni recently gathered to celebrate the 10th anniversary of the GSK acquisition at an alumni reunion event sponsored by Kymanox and BioIT Solutions, two renowned companies founded by HGS Alumni. The event brought together 140 alumni, including a veritable “who’s, who” of BHCR entrepreneurs, founders and key thought leaders that once called HGS home and then went on to new heights. The post Human Genome Sciences Alumni: Where Are They Now? appeared first on BioBuzz.

Human Genome Sciences Frequently Asked Questions (FAQ)

  • When was Human Genome Sciences founded?

    Human Genome Sciences was founded in 1992.

  • Where is Human Genome Sciences's headquarters?

    Human Genome Sciences's headquarters is located at 14200 Shady Grove Road, Rockville.

  • What is Human Genome Sciences's latest funding round?

    Human Genome Sciences's latest funding round is Acq - P2P.

  • Who are the investors of Human Genome Sciences?

    Investors of Human Genome Sciences include GSK and Rho Ventures.

  • Who are Human Genome Sciences's competitors?

    Competitors of Human Genome Sciences include Aerie, GangaGen, Endocyte, Keryx Biopharmaceuticals, Raptor Pharmaceutical Corp. and 13 more.

Compare Human Genome Sciences to Competitors

Longevica Logo
Longevica

Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.

A
ATNT

ATNT is a biotech company which develops cross-disciplinary engineering methods, to find the most effective molecular targets for treatment of complex human disorders.

B
Bolder BioTechnology

Bolder BioTechnology, Inc. uses advanced protein engineering technologies to create human protein pharmaceuticals with enhanced therapeutic properties. Most protein pharmaceuticals are rapidly eliminated by the body, which limits their effectiveness and requires that they be administered by frequent, often daily, injection. The company's products are designed to last longer in the body, which aims to allow them to be administered less frequently, e.g., once per week to once per month, and maximizes their therapeutic benefits to patients. Company scientists combine protein structure/function information with targeted protein modification technologies to rationally design long-acting protein pharmaceuticals that, in many cases, are 10-100-fold more potent than competing products prepared using non-targeted protein modification technologies. Bolder BioTechnology has a robust pipeline of products in preclinical development, including products for the treatment of hematological and endocrine disorders, cancer and infectious disease. The company intend to commercialize these products independently and through strategic alliances with corporate partners.

A
Arisyn Therapeutics

Arisyn Therapeutics Inc. is a biotechnology company focused on the development of first in class inhibitors of infectious disease and cancer. Arisyn possesses a portfolio of small molecule compounds that will be developed to treat Human Immunodeficiency Virus-Type 1 (HIV-1), Human Immunodeficiency Virus-Type 2 (HIV-2), Human T-Lymphotropic Virus-Type 1 (HTLV-1), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Herpes Simplex Virus-Type 2 (HSV-2). Arisyn will perform all necessary studies required to develop these therapeutic agents through Phase 1 and Phase 2 human clinical trials.

S
Spaltudaq

Spaltudaq Corporation, a privately-held biotechnology company based in Seattle, is focused on developing therapeutic antibodies for the treatment of inflammation, infectious disease and cancer. Our technology harnesses the power of the human immune system to identify tumor-specific or pathogen-specific monoclonal antibodies from human tissue samples.

Oligomerix Logo
Oligomerix

Oligomerix is a clinical-stage biotechnology company. It focuses on developing disease-modifying therapeutics for neurodegenerative diseases characterized by the aberrant tau protein, ranging from tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The firm serves clients in the healthcare sector. Oligomerix was founded in 2006 and is based in West Harrison, New York.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.